“This novel approach using a liposomal system and fluorescence-based technology is shown to be suitable to study whether marketed drugs and drug candidates are P-glycoprotein inhibitors. The assay is rapid and requires minimal quantities of test drug. The method is amenable to robotics and offers a cost advantage relative to conventional cell-based assays. The well-defined nature of this assay also obviates many of the inherent complications and ambiguities of cell-based systems”
– Director, Merck

“We have tested the Fluorosome-trans-pgp inhibition assay. We were pleased with the results. It is a simple, rapid and direct method for measurement of drug transport.  The assay is readily modified to a small volume, 384-well format for higher throughput. It has the potential to replace the existing cumbersome methods.”
– Senior Scientist, Major Pharmaceutical Company

“We have finished the Fluorosome-trans-pgp evaluation study and are encouraged with the data. It has the potential to replace the existing methods, and we look forward to the availability of other transporter substrate assays.”
– Senior Investigator, Pharmaceutical Company

“Results from our in-house validation of the Fluorosome-trans-pgp reagent closely reproduced published values and correlated well with our MDCK-MDR1 model.  Ease of use and the absence of confounding transporters set TFC’s platform apart and, we are excited to test their forthcoming transporter offerings. ”
– Scientist, Vertex Pharmaceuticals